Abstract
The importance of the trace element selenium for human health is well established. Selenium plays a central role in the formation of selenocysteine, a modified amino acid located in the catalytic center of selenoenzymes. The crucial role of selenium in these enzymes revolves around the maintenance of many redox systems in cellular and extracellular compartments. In addition, selenium plays an important role in thyroid hormone metabolism. Several clinical trials of selenium supplementation in critically ill patients have been conducted to date, providing an interesting and provoking mix of findings. Despite some promising results, no definitive answers regarding the effects of selenium supplementation on critically ill patient mortality or morbidity exist. Further research in the setting of well-designed, prospective, randomized trials is necessary to better define the role of selenium supplementation in critically ill patients.
Keywords: Selenium supplementation, intensive care unit, critically ill patients, review of clinical trials
Mini-Reviews in Medicinal Chemistry
Title: Current Evidence from Phase III Clinical Trials of Selenium Supplementation in Critically Ill Patients: Why Should We Bother?
Volume: 7 Issue: 7
Author(s): S. Peter Stawicki, Melanie Lyons, Marianne Aloupis, Babak Sarani, S. Peter Stawicki, Melanie Lyons, Marianne Aloupis and Babak Sarani
Affiliation:
Keywords: Selenium supplementation, intensive care unit, critically ill patients, review of clinical trials
Abstract: The importance of the trace element selenium for human health is well established. Selenium plays a central role in the formation of selenocysteine, a modified amino acid located in the catalytic center of selenoenzymes. The crucial role of selenium in these enzymes revolves around the maintenance of many redox systems in cellular and extracellular compartments. In addition, selenium plays an important role in thyroid hormone metabolism. Several clinical trials of selenium supplementation in critically ill patients have been conducted to date, providing an interesting and provoking mix of findings. Despite some promising results, no definitive answers regarding the effects of selenium supplementation on critically ill patient mortality or morbidity exist. Further research in the setting of well-designed, prospective, randomized trials is necessary to better define the role of selenium supplementation in critically ill patients.
Export Options
About this article
Cite this article as:
S. Peter Stawicki , Melanie Lyons , Marianne Aloupis , Babak Sarani , Stawicki Peter S., Lyons Melanie, Aloupis Marianne and Sarani Babak, Current Evidence from Phase III Clinical Trials of Selenium Supplementation in Critically Ill Patients: Why Should We Bother?, Mini-Reviews in Medicinal Chemistry 2007; 7 (7) . https://dx.doi.org/10.2174/138955707781024526
DOI https://dx.doi.org/10.2174/138955707781024526 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rational Targeting of Peroxisome Proliferating Activated Receptor Subtypes
Current Medicinal Chemistry Natural Polyphenols and Cardioprotection
Mini-Reviews in Medicinal Chemistry Cardiac Stem Cell Regeneration in Metabolic Syndrome
Current Pharmaceutical Design Between Bench and Bed Side: PI3K Inhibitors
Current Molecular Pharmacology Pituitary Dysfunction as a Cause of Cardiovascular Disease
Current Pharmaceutical Design Sirtuins: Possible Clinical Implications in Cardio and Cerebrovascular Diseases
Current Drug Targets Demystifying the ACE Polymorphism: From Genetics to Biology
Current Pharmaceutical Design New and Under Explored Epigenetic Modulators in Search of New Paradigms
Medicinal Chemistry Ionophores as Potent Anti-malarials: A Miracle in the Making
Current Topics in Medicinal Chemistry The Role of Integrin-Mediated Cell Adhesion in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Pharmaceutical Design Cord Blood as Diagnostic Window for Preeclampsia
Recent Patents on Biomarkers Cellular Senescence in Cardiovascular Diseases: Potential Age-Related Mechanisms and Implications for Treatment
Current Pharmaceutical Design Do You See What I See: Recognition of Protozoan Parasites by Toll-Like Receptors
Current Immunology Reviews (Discontinued) Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Current Cardiology Reviews New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design Material-Based Engineering Strategies for Cardiac Regeneration
Current Pharmaceutical Design Cardiotonic Steroids in Adaptation to Dietary Salt Intake
Current Clinical Pharmacology Mutation p.S335X in GATA4 Reduces its DNA Binding Affinity and Enhances Cell Apoptosis Associated with Ventricular Septal Defect
Current Molecular Medicine Mitochondrial Biogenesis: A Therapeutic Target for Neurodevelopmental Disorders and Neurodegenerative Diseases
Current Pharmaceutical Design